Battery-powered patch delivers drugs for peripheral artery disease

Scientists say that problems with injected treatments for peripheral artery disease (PAD) could be solved by a skin patch hooked up to a battery. Caused by blocked arteries in the leg, PAD can be pretty painful. The treatment includes administering fibroblast growth factors (FGFs), which are proteins that take care of PAD along with other skin conditions. The trouble is, FGFs cannot be taken orally and injections cause other side effects like kidney and eye damage. So, FGFs become a drug-delivery problem in search of a solution.

Swiss researcher Yogeshvar Kalia, writing in the journal Molecular Pharmaceutics, believes he's found an answer in a drug-delivery technology called transdermal iontophoresis. The technique uses a small electric current and is already proven to deliver meds made from small proteins. But nobody knew whether it would work for larger ones like FGFs.

So, Kalia and colleagues tried a couple of experiments--first on pig skin samples, then on human. They zapped the FGFs into the skin and it worked. In fact, four times as much of the medication remained on the skin, and biologically active, than passed through it. That means larger proteins, like FGFs, can be delivered through iontophoresis. This opens up the delivery method for other skin diseases.

- read the release from the American Chemical Society
- Medical News Today filed a report
- and here's the abstract in Molecular Pharmaceutics

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.